Although post-transplantation lymphoproliferative disease (PTLD) after liver transplantation is very rare, its prognosis is worse than that of PTLD following other types of solid organ transplantation. Here, we report a rare case of early onset polymorphic PTLD in a graft liver occurring five months after deceased-donor liver transplantation due to hepatocellular carcinoma and hepatitis C virus infection. Initially, findings from contrast-enhanced magnetic resonance imaging mistakenly suspected the lesion was a necrotizing abscess with central necrosis. However, 18 F-fluorodeoxyglucose positron emission tomography and biopsy findings confirmed an Epstein-Barr virus (EBV)-associated, B cell type polymorphic PTLD with central necrosis. Our case suggests regular monitoring of EBV serologic status for liver transplant recipients who were initially in an EBV seronegative state. Although early-onset PTLD is very rare after liver transplantation, PTLD should be suspected when recipients show the seroconversion for EBV proteins and the development of new tumors with various clinical presentations. (J Liver Cancer 2019;19:165-170) IntroductIon Post-transplantation lymphoproliferative disease (PTLD) is one of the most common neoplastic diseases in recipients of solid organ transplantation (SOT). 1,2 Previous reports have demonstrated that approximately 70% of PTLD cases are associated with an Epstein-Barr virus (EBV) infection and the use of immunosuppressive drugs. 2 A mismatch between EBV seropositive donor and EBV seronegative recipient can result in the development of PTLD with a 4.7-fold higher hazard ratio compared to the matched EBV seropositive recipients. 2 Though the exact pathogenesis is unclear, EBV-associated PTLD may be caused by the decrease in EBV-specific cytotoxic T-cells in recipients and the proliferation of EBV-infected B cells from the donor. 3 Life-long intake of immunosuppressive agents increases the incidence of PTLD after liver transplantation. Individual medications that are reported as potential risk factors for PTLD are anti-thymocyte globulin, calcineurin inhibitors, anti-CD3, tacrolimus, and cyclosporine. 2,4-7 Approximately half of the cases of reported PTLD occur in transplanted organs, such as the heart, lung, and liver. 6,8 As the survival rates for SOT patients have increased recently, the majority of PTLD cases are late onset cases. 9 Early onset 166
PTLD, developing within the first six months after transplantation, rarely occurs after liver transplantation. 10 Here, we report an early-onset EBV-associated polymorphic PTLD in a graft liver, which was initially suspected to be a necrotizing abscess with central necrosis by contrast-enhanced abdominal magnetic resonance imaging (MRI), but diagnosed as polymorphic PTLD after 18 cASE rEPort
History and presentation
The present case report was approved by the Institutional Review Boards (Seoul St. Mary's Hospital, KC19ZESI0149).
A 54-year-old male patient was admitted for the evaluation of a hepatic mass. The patient had undergone deceased-donor liver transplantation (LT) for hepatocellular carcinoma (HCC) (Modified UICC 5th stage II, T2N0M0, Barcelona Clinic Liver Cancer stage: A) due to chronic hepatitis C virus (HCV) infection. The patient had been diagnosed with HCC three years prior to liver transplantation and had undergone trans-arterial chemoembolization nine times. At the time of liver transplantation, the viable tumor was 1 cm in size. After surgery, the patient was prescribed 400 mg cyclosporin, 1,000 mg mycophenolate mofetil, and 5 mg prednisolone daily. Five months later, the patient was admitted to the hospital for a follow-up examination during a state of complete remission of HCC with no specific symptoms.
Investigations
Investigations revealed normal ranges of complete blood count, blood chemistry, and tumor markers and elevated serum lactate dehydrogenase levels (456 µg/dL). HCV RNA level was 5,452,120 IU/mL indicating a recurrence of HCV.
Contrast-enhanced abdominal MRI detected a 7 cm irregular necrotizing mass with rim enhancement in the right hemiliver mimicking a necrotizing abscess ( Fig. 1A ). 18 
Treatment and outcome
The patient underwent direct-acting antiviral treatment (le-dipasvir, sofosbuvir, and ribavirin) for recurrent HCV infection while simultaneously discontinuing cyclosporin and mycophenolate mofetil. As a substitute for immunosuppressants, After the completion of chemotherapy, response evaluation 
dIScuSSIon
The highest incidence of PTLD following SOT occurs in intestinal and multi-organ transplants (5-20%), and the lowest incidence occurs in kidney and liver transplants (1-5%). 6 In comparison to other organ transplantations with prolonged use of immunosuppressants, PTLD associated with liver or kidney transplants occurs at a lower rate due to the reduced dose and administration duration of immunosuppressants. 11 Previous reports demonstrated that PTLD after liver transplantation appeared most commonly in liver grafts (approximately 20%). 12 PTLD following liver transplantation typically occurs more than one year after the transplant in adults, because this is the period where patients receive long-term immunosuppressant treatment. 10 Generally, 60-80% of all PTLD cases are EBV-related, 13 toxic T-cells. 12 In this setting, EBV-driven lymphoproliferation with type 3 latency may occur and is labeled PTLD. 12 HCV infection has also been reported as a possible risk factor for non-Hodgkin's lymphoma, especially for B cell lymphoma. 15 Although there is no standard treatment approved for the management of PTLD due to its clinical and pathological heterogeneity, the initial treatment typically involves a reduction in immunosuppression and a renewal of immune surveillance. The restoration of immune function allows the body to control EBV-infected proliferating cells. 6 Both European and American guidelines also suggest a reduction in anti-proliferative agents such as mycophenolate mofetil and azathioprine, and switching to a mammalian target of rapamycin inhibitor, such as everolimus in this case. 3 In the cases of CD20-positive PTLD with extrahepatic invasion or resistance to immunosuppressant reduction, rituximab is considered as the first-line treatment. 19 The treatment response of first-line rituximab appeared to be 40-65%. 19 Early introduction of rituximab in patients with PTLD is reported to confer better survival outcomes. 20 In cases of rituximabresistant PTLD or high-grade lymphoma or multi-organ in-volved PTLD, R-CHOP is recommended. 6 For CD20-positive PTLD patients with rituximab-included regimen resistance, cytotoxic chemotherapy is considered a possible modality; however, the overall prognosis appeared to be worse when compared to that with rituximab-responsive PTLD. 4 Other treatments such as surgical resection and radiotherapy for local control may be recommended for patients with resistance to the first-line treatment, but they may carry adverse side effects. 4 Prognosis of PTLD following SOT is poor with a 60% and 
